Your browser doesn't support javascript.
loading
Correction to: Phase 1 dose-escalation study of a novel oral PI3K/mTOR dual inhibitor, LY3023414, in patients with cancer.
Kondo, Shunsuke; Tajimi, Masaomi; Funai, Tomohiko; Inoue, Koichi; Asou, Hiroya; Ranka, Vinay Kumar; Wacheck, Volker; Doi, Toshihiko.
Afiliação
  • Kondo S; Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan. shkondo@ncc.go.jp.
  • Tajimi M; Eli Lilly Japan K.K, Kobe, Japan.
  • Funai T; Eli Lilly Japan K.K, Kobe, Japan.
  • Inoue K; Eli Lilly Japan K.K, Kobe, Japan.
  • Asou H; Eli Lilly Japan K.K, Kobe, Japan.
  • Ranka VK; Eli Lilly Services India Private Limited, Bengaluru, India.
  • Wacheck V; Eli Lilly GmbH, Vienna, Austria.
  • Doi T; Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba, Japan.
Invest New Drugs ; 38(6): 1846, 2020 Dec.
Article em En | MEDLINE | ID: mdl-32894386
ABSTRACT
The article Phase 1 dose-escalation study of a novel oral PI3K/mTOR dual inhibitor, LY3023414, in patients with cancer, written by Shunsuke Kondo, Masaomi Tajimi, Tomohiko Funai, Koichi Inoue, Hiroya Asou, Vinay Kumar Ranka, Volker Wacheck, Toshihiko Doi, was originally published electronically on the publisher's internet portal on 23 June 2020 without open access.
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Invest New Drugs Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Japão
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Invest New Drugs Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Japão